Samuel Charles Fehling, PhD

☏ (262) 203-0728 | ⚲ Hoover, Alabama | 🖥 career.nerdyspace.net | ✉ sfehling@nerdyspace.net

Professional Profile

- Detail oriented & driven cancer researcher with 10 years of lab experience
- Successfully designed and executed experiments to evaluate novel drug combinations for liver cancer patients & develop numerous molecular diagnostic assays across multiple PCR platforms

Education

University of Alabama at Birmingham (UAB) ⚲ Birmingham, AL

Doctor of Philosophy in Biomedical Sciences December 2019

University of Wisconsin – Eau Claire (UWEC) ⚲ Eau Claire, WI

Bachelor of Science in Biochemistry & Molecular Biology May 2014

Work Experience

Research Biologist at BioCryst Pharmaceuticals 2022 – Present

- Design, validate & conduct *in vitro* biological and immunological assays for the pharmacological characterization of new small molecule drug candidates.
- Design & conduct *in vivo* studies for evaluating new drug candidates and current investigational drugs for efficacy in disease models & pharmacokinetics in rodents.

Research & Development Scientist at BioGX 2020 – 2022

- Developed molecular diagnostic assays for custom order & FDA EUA approved products.
- Skilled in various industry areas including R&D, Quality Control & training of personnel.
- Assisted in developing new product line, product platform conversions & a new PCR platform.
- Experienced in PCR platforms including BD MAX, QuantStudio, Bio-Rad CFX & ABI 7500.
- Improved upon current procedures & approaches to save development down-time & money spent.

University of Alabama at Birmingham (UAB) Graduate Research Assistant 2014 – 2019

- Developed & analyzed therapeutic drug combinations for use in liver cancer (cholangiocarcinoma).
- Devised a variety of techniques to develop & characterize preclinical chemotherapeutic resistant liver cancer models.
- Experienced with athymic nude & C57BL/6 mice, oral gavage, intraperitoneal (IP) injection & patient derived xenograft (PDX) models.

Selected Publications

Aubrey L. Miller, **Samuel C. Fehling**, Rebecca B. Vance, Dongquan Chen, Eric Josh Brown, M Iqbal Hossain, Eric O. Heard, Shaida Andrabi, Hengbin Wang, Eddy S. Yang, Donald J. Buchsbaum, Robert CAM van Waardenburg, Susan L. Bellis, Karina J. Yoon (2024). *BET Inhibition Decreases HMGCS2 and Sensitizes Resistant Pancreatic Tumors to Gemcitabine.* Cancer Letters.

Aubrey L. Miller, Patrick L. Garcia, **Samuel C. Fehling**, Tracy L. Gamblin, Rebecca B. Vance, Leona N. Council, Dongquan Chen, Eddy S. Yang, Robert CAM van Waardenburg, Karina J. Yoon (2021). *The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer.* Cancers.

Samuel C. Fehling, Aubrey L. Miller, Patrick L. Garcia, Rebecca B. Vance, Karina J. Yoon (2019). *The Combination of BET and PARP Inhibitors is Synergistic in Models of Cholangiocarcinoma.* Cancer Letters.

Version: 24.5.9